New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTDKS, ALKS, CBRL, BCEI, VAR, MDCO, ARQL, ARIAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Citigroup... Alkermes (ALKS) initiated with a Buy at Citigroup... ArQule (ARQL) initiated with a Buy at Citigroup... Bonanza Creek Energy (BCEI) initiated with a Buy at SunTrust... Dick's Sporting (DKS) initiated with a Market Perform at BMO Capital... The Medicines Co. (MDCO) initiated with a Neutral at Citigroup... Varian Medical (VAR) initiated with a Buy at Brean Capital... Cracker Barrel (CBRL) initiated with a Buy at CL King.
News For ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 2, 2015
12:40 EDTMDCOMedicines Co. says appeals court rules against company in Angiomax litigation
Subscribe for More Information
10:17 EDTMDCOAppeals court reverses lower court patent ruling in Medicines Co. case
The Medicines Company (MDCO) owns U.S. patent no. 7,582,727 and U.S. patent no. 7,598,343, which relate to the drug bivalirudin, a synthetic peptide used as an anti-coagulant that the company sells under the Angiomax brand. On August 19, 2010, The Medicines Company sued Hospira (HSP), alleging that two of Hospira’s ANDA filings infringe claims 1–3, 7–10, and 17 of the ’727 patent and claims 1–3 and 7–11 of the ’343 patent. A district court previously construed the asserted claims and, after a bench trial, found the patents not infringed and not invalid as obvious, indefinite, or under the on-sale bar. The Medicines Company appealed the U.S. District Court for the District of Delaware’s claim construction and non-infringement findings, while Hospira, crossappealed the district court’s determination that the asserted claims are not invalid under the on-sale bar, obviousness, or indefiniteness. The U.S. Court of Appeals for the Federal Circuit has now concluded that the district court "clearly erred" in finding that the bivalirudin batches prepared by Ben Venue Laboratories before the critical date were not sold to The Medicines Company and were prepared primarily for an experimental purpose. Accordingly, the federal appeals court reversed the district court’s validity determination and held the asserted claims invalid under the onsale bar. Shares of Medicines Co., which initially fell amid headlines regarding the ruling, are now up 4.5% to $29.61, while Hospira is flat at $88.90.
10:04 EDTMDCOHigh option volume stocks
Subscribe for More Information
09:57 EDTMDCOMedicines Co. loses appeal in Hospira suit over Angiomax patents, Bloomberg says
Subscribe for More Information
09:50 EDTMDCOThe Medicines Co. drops 3.2% to $27.43 in early trading
Subscribe for More Information
June 30, 2015
10:01 EDTBCEIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:44 EDTBCEIBonanza Creek initiated with a Buy at Canaccord
Subscribe for More Information
June 29, 2015
18:04 EDTCBRLS&P announces changes to the S&P 400, 600 indices
S&P SmallCap 600 constituent Cracker Barrel Old Country Store (CBRL) will replace Dresser-Rand Group (DRC) in the S&P MidCap 400, and Marten Transport (MRTN) will replace Cracker Barrel Old Country Store in the S&P SmallCap 600 after the close of trading on Wednesday, July 1. Siemens AG (SIEGY) is acquiring Dresser-Rand Group in a deal expected to be completed soon.
17:18 EDTCBRLMarten Transport to replace Cracker Barrel in S&P 600 as of 7/1 close
17:18 EDTCBRLCracker Barrel to replace Dresser-Rand in S&P 400 as of 7/1 close
Subscribe for More Information
June 26, 2015
07:52 EDTALKSAlkermes schizophrenia drug profile looks interesting, says Cowen
Subscribe for More Information
07:15 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg reports
The Medicines Co. is working with advisers from Rothschild on a review of strategic options for its European business, according to Bloomberg, citing people familiar with the matter. The review, which is at an advanced stage, may lead to a sale, licensing agreement or partnership, the report added. Reference Link
June 25, 2015
14:38 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg says
June 24, 2015
15:53 EDTDKSSunTrust identifies the most likely M&A activity in specialty retail
Subscribe for More Information
07:48 EDTALKSAlkermes data support ALKS 3831 potential, says Credit Suisse
Subscribe for More Information
05:51 EDTALKSAlkermes physician call on ALKS 3831 encouraging, says UBS
Subscribe for More Information
June 23, 2015
08:41 EDTCBRLCracker Barrel sees three year operating income/EPS CAGR 7%-8%
Expects to realize $50M of annual cost reductions by FY17. Sees three-year operating income/EPS CAGR of 7%-8%. Targeting 100bps margin improvement by FY17. Says "committed" to shareholder return. Says YTD results are strong, with comparable store traffic increased 1.8%, comparable store restaurant sales increased 5.2% and comparable store retail sales increased 4.5% compared to the prior-year Q3. Says adjusted YTD EPS increased 21% over prior year period. Sees about 4% annual top line growth from FY14-FY17, with annual SSS traffic flat to up 0.5%, retail SSS up 2%-3%, new unit growth about 1.5%. Expects total price increases over the next three years of 2%-3% annually. Comments from slides that will be presented at the Oppenheimer 15th Annual Consumer Conference.
07:15 EDTCBRLOppenheimer to hold a conference
Subscribe for More Information
June 22, 2015
16:37 EDTMDCOThe Medicines Co. to hold a conference call
Subscribe for More Information
14:33 EDTMDCOThe Medicines Co. antiplatelet drug approved by FDA
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use